University of Texas Health Science Center at Houston, Division of Renal Diseases & Hypertension, Houston, Texas 77030, USA.
ASAIO J. 2012 Sep-Oct;58(5):443-9. doi: 10.1097/MAT.0b013e31825f3446.
Liver failure is associated with a high morbidity and mortality rate and is the seventh leading cause of death worldwide. Orthotopic liver transplantation remains the definitive treatment; however, because of the limited number of available organs many patients expire while on the transplant list. Currently, there are no established means for providing liver support as a means of bridging patients to transplantation or allowing for recovery from liver injury. Analogous to the clinical situation of renal failure, there is great interest in developing liver support systems that replace the metabolic and waste removal functions of the liver. These support systems are of two general types: artificial and bioartificial livers. In this review, based on a presentation from the 57th American Society of Artificial Internal Organs Annual Meeting (Washington, D.C., June 2011), we review the current status of liver support systems.
肝衰竭与高发病率和死亡率相关，是全球第七大致死原因。原位肝移植仍然是确定性治疗方法；然而，由于可供使用的器官数量有限，许多患者在等待移植期间死亡。目前，尚无确立的方法来提供肝脏支持，以作为将患者桥接至移植或允许从肝损伤中恢复的手段。类似于肾衰竭的临床情况，人们对开发替代肝脏的代谢和废物清除功能的肝脏支持系统非常感兴趣。这些支持系统有两种一般类型：人工和生物人工肝脏。在这篇综述中，我们根据第 57 届美国人工内部器官学会年会（华盛顿特区，2011 年 6 月）的演讲，回顾了肝脏支持系统的现状。
